Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Otosynalar is a fixed-dose combination otic solution developed by Laboratorios Osorio de Moraes for the treatment of inflammatory and infectious conditions of the external ear canal, including acute external otitis and associated otalgia. The formulation combines fluocinolone acetonide, a synthetic corticosteroid with anti-inflammatory and antipruritic properties; neomycin sulfate and polymyxin B sulfate, which provide broad-spectrum antibacterial coverage against common otic pathogens; and lidocaine hydrochloride, a local anesthetic that provides symptomatic relief from ear pain. It is typically administered as ear drops and has been evaluated in Phase III clinical trials in Brazil as a reference treatment for symptomatic control of ear pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Otosynalar.